Bashar W. Badran

Bashar W. Badran

Auto-generated profile, based on publicly available information

Bashar W. Badran

Medical University of South Carolina

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in Brain Stimulation
Verified
Journal Article
Closed access
BBBashar W. Badran
Bashar W. Badran
LDLogan T. Dowdle
Logan T. Dowdle
OMOliver J. Mithoefer
Oliver J. Mithoefer
NLNicholas T. LaBate
Nicholas T. LaBate
JCJames Coatsworth
James Coatsworth
MGMark S. George
Mark S. George

6 September 2021 in Neuromodulation: Technology at the Neural Interface
Verified
Journal Article
Open access
PDF file
CAChristopher W. Austelle
Christopher W. Austelle
GOGeorgia H. O'LEary
Georgia H. O'LEary
STSean Thompson
Sean Thompson
EGElise Gruber
Elise Gruber
AKAlex Kahn
Alex Kahn
BBBashar W. Badran
Bashar W. Badran
Objectives Vagus nerve stimulation (VNS) is reemerging as an exciting form of brain stimulation, due in part to the development of its noninvasive counterpart transcutaneous auricular VNS. As the field grows, it is important to understand where VNS emerged from, including its history and the studies that were conducted over the past four decades. Here, we offer a comprehensive review of the history of VNS in the treatment of major depression. Materials and Methods Using PubMed, we reviewed the history of VNS and aggregated the literature into a narrative review of four key VNS epochs: 1) early invention and development of VNS, 2) path to Food and Drug Administration (FDA) approval for depression, 3) refinement of VNS treatment parameters, and 4) neuroimaging of VNS. Results VNS was described in the literature in the early 1900s; however, gained traction in the 1980s as Zabara and colleagues developed an implantable neurocybernetic prosthesis to treat epilepsy. As epilepsy trials proceed in the 1990s, promising mood effects emerged and were studied, ultimately leading to the approval of VNS for depression in 2005. Since then, there have been advances in understanding the mechanism of action. Imaging techniques like functional magnetic resonance imaging and positron emission tomography further aid in understanding direct brain effects of VNS. Conclusions The mood effects of VNS were discovered from clinical trials investigating the use of VNS for reducing seizures in epileptic patients. Since then, VNS has gone on to be FDA approved for depression. The field of VNS is growing, and as noninvasive VNS quickly advances, it is important to consider a historical perspective to develop future brain stimulation therapies.

1 July 2018 in Brain Stimulation
Verified
Journal Article
Closed access
BBBashar W. Badran
Bashar W. Badran
OMOliver J. Mithoefer
Oliver J. Mithoefer
CSCaroline E. Summer
Caroline E. Summer
NLNicholas T. LaBate
Nicholas T. LaBate
CGChloe E. Glusman
Chloe E. Glusman
MGMark S. George
Mark S. George

13 July 2021 in Frontiers in Neuroscience
Verified
Journal Article
Open access
STSean L. Thompson
Sean L. Thompson
GOGeorgia H. O’leary
Georgia H. O’leary
CAChristopher W. Austelle
Christopher W. Austelle
EGElise Gruber
Elise Gruber
AKAlex T. Kahn
Alex T. Kahn
BBBashar W. Badran
Bashar W. Badran
Vagus nerve stimulation (VNS) is an established form of neuromodulation with a long history of promising applications. Earliest reports of VNS in the literature date to the late 1800’s in experiments conducted by Dr. James Corning. Over the past century, both invasive and non-invasive VNS have demonstrated promise in treating a variety of disorders, including epilepsy, depression, and post-stroke motor rehabilitation. As VNS continues to rapidly grow in popularity and application, the field generally lacks a consensus on optimum stimulation parameters. Stimulation parameters have a significant impact on the efficacy of neuromodulation, and here we will describe the longitudinal evolution of VNS parameters in the following categorical progression: (1) animal models, (2) epilepsy, (3) treatment resistant depression, (4) neuroplasticity and rehabilitation, and (5) transcutaneous auricular VNS (taVNS). We additionally offer a historical perspective of the various applications and summarize the range and most commonly used parameters in over 130 implanted and non-invasive VNS studies over five applications.

1 December 2015 in Brain Research
Verified
Journal Article
Closed access
CHColleen A Hanlon
Colleen A Hanlon
LDLogan T. Dowdle
Logan T. Dowdle
CAChristopher W. Austelle
Christopher W. Austelle
WDWilliam DeVries
William DeVries
OMOliver Mithoefer
Oliver Mithoefer
MGMark S. George
Mark S. George

1 November 2020 in Brain Stimulation
Verified
Journal Article
Open access
BBBashar W. Badran
Bashar W. Badran
KCKevin A. Caulfield
Kevin A. Caulfield
SSSasha Stomberg-Firestein
Sasha Stomberg-Firestein
PSPhilipp M. Summers
Philipp M. Summers
LDLogan T. Dowdle
Logan T. Dowdle
MGMark S. George
Mark S. George
Transcranial focused ultrasound (tFUS) is a noninvasive brain stimulation method that may modulate deep brain structures. This study investigates whether sonication of the right anterior thalamus would modulate thermal pain thresholds in healthy individuals. We enrolled 19 healthy individuals in this three-visit, double-blind, sham-controlled, crossover trial. Participants first underwent a structural MRI scan used solely for tFUS targeting. They then attended two identical experimental tFUS visits (counterbalanced by condition) at least one week apart. Within the MRI scanner, participants received two, 10-min sessions of either active or sham tFUS spread 10 min apart targeting the right anterior thalamus [fundamental frequency: 650 kHz, Pulse repetition frequency: 10 Hz, Pulse Width: 5 ms, Duty Cycle: 5%, Sonication Duration: 30s, Inter-Sonication Interval: 30 s, Number of Sonications: 10, ISPTA.0 995 mW/cm2, ISPTA.3 719 mW/cm2, Peak rarefactional pressure 0.72 MPa]. The primary outcome measure was quantitative sensory thresholding (QST), measuring sensory, pain, and tolerance thresholds to a thermal stimulus applied to the left forearm before and after right anterior thalamic tFUS. The right anterior thalamus was accurately sonicated in 17 of the 19 subjects. Thermal pain sensitivity was significantly attenuated after active tFUS. The pre-post x active-sham interaction was significant (F(1,245.95) = 4.03, p = .046). This interaction indicates that in the sham stimulation condition, thermal pain thresholds decreased 1.08 °C (SE = 0.28) pre-post session, but only decreased .51 °C (SE = 0.30) pre-post session in the active stimulation group. Two 10-min sessions of anterior thalamic tFUS induces antinociceptive effects in healthy individuals. Future studies should optimize the parameter space, dose and duration of this effect which may lead to multi-session tFUS interventions for pain disorders.